Get the Stockscreener App
0.42
1.20%
-0.0051
After Hours:
.40
-0.02
-4.76%
Spruce Biosciences Inc stock is traded at $0.42, with a volume of 346.45K.
It is down -1.20% in the last 24 hours and up +12.36% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
See More
Previous Close:
$0.4251
Open:
$0.401
24h Volume:
346.45K
Relative Volume:
0.61
Market Cap:
$17.35M
Revenue:
$7.10M
Net Income/Loss:
$-39.43M
P/E Ratio:
-0.4468
EPS:
-0.94
Net Cash Flow:
$-46.50M
1W Performance:
+3.58%
1M Performance:
+12.36%
6M Performance:
-12.17%
1Y Performance:
-91.86%
1-Day Range:
$0.3905
$0.446
1-Week Range:
$0.381
$0.446
52-Week Range:
$0.3421
$5.95
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
0.42 | 17.35M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
Spruce Biosciences, Inc. (SPRB) Reports Q2 Loss, Tops Revenue Estimates - MSN
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
Spruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
NeoGenomics (NEO) Tops Q4 Earnings Estimates - Yahoo Finance
The Prothena Corporation plc (PRTA) had a good session last reading, didn’t it? - US Post News
Alamos Gold Inc. (TSE:AGI) Receives C$28.78 Average Target Price from Brokerages - Defense World
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $3.90 Consensus Target Price from Analysts - Defense World
Spruce Biosciences Inc [SPRB] Investment Appeal on the Rise - Knox Daily
Spruce Biosciences Inc (NASDAQ: SPRB) Stock Has Gained 4.05% Over The Month – Is There Room For Growth? - Marketing Sentinel
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel
Spruce Biosciences Inc (SPRB) Stock Price and Analyst Predictions - The News Heater
Spruce Biosciences Inc (NASDAQ:SPRB) stock: You might be surprised - US Post News
Examining OppFi Inc (OPFI) stock is warranted - US Post News
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $3.90 Consensus Target Price from Brokerages - Defense World
After A 1.47% Jump In The Last Week, Does Amprius Technologies Inc (NYSE: AMPX) Still Make Sense To Buy? - Marketing Sentinel
CMS’ price negotiations take two: Ozempic, Xtandi among 15 drugs chosen - BioWorld Online
Neurocrine Sues to Clear New Drug of Spruce's Patent 'Ransom' - Bloomberg Law
Spruce Biosciences, Inc. (NASDAQ:SPRB) Sees Large Decrease in Short Interest - Defense World
Mapletree Industrial Trust (OTCMKTS:MAPIF) Short Interest Down 50.6% in December - Defense World
SPRB stock touches 52-week low at $0.36 amid market challenges - Investing.com Australia
SPRB stock touches 52-week low at $0.36 amid market challenges By Investing.com - Investing.com South Africa
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Congenital Adrenal Hyperplasia Pipeline Analysis 2024: FDA Approvals and Emerging Therapies | Becton, Dickinson and Company, Cook Medical, Cooper Surgical, Smiths Medical, Rocket Medical, CENTOGENE - Barchart
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Spruce Biosciences Appoints Interim Chief Medical Officer - MSN
Enovix Appoints Kristina Truong as Chief Accounting Officer - Yahoo Finance
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $3.90 Consensus PT from Analysts - Defense World
Spruce Biosciences names new interim CMO By Investing.com - Investing.com Canada
Spruce Biosciences names new interim CMO - Investing.com
Congenital Adrenal Hyperplasia Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - The Globe and Mail
SPRB stock touches 52-week low at $0.37 amid market challenges - Investing.com
Neurocrine Biosciences launches Crenessity in USA - The Pharma Letter
HC Wainwright Has Bullish Estimate for SPRB FY2024 Earnings - Defense World
Spruce Biosciences (NASDAQ:SPRB) Given “Neutral” Rating at HC Wainwright - Defense World
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why - MSN
Blockbuster bound? Neurocrine’s hyperplasia drug approved - BioWorld Online
Spruce Biosciences’ (SPRB) Neutral Rating Reiterated at Guggenheim - Defense World
Adobe (NASDAQ:ADBE) Cut to “Hold” at TD Cowen - Defense World
FY2024 Earnings Forecast for SPRB Issued By Leerink Partnrs - Defense World
Needham & Company LLC Reiterates Buy Rating for Recursion Pharmaceuticals (NASDAQ:RXRX) - Defense World
Rigel Pharmaceuticals’ (RIGL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Spruce Biosciences (NASDAQ:SPRB) Earns “Market Perform” Rating from Oppenheimer - Defense World
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):